盈健醫療
HUMAN HEALTH

Human Health Holdings Limited
盈健醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1419)

ANNOUNCEMENT ON ESTIMATED PROFIT DECREASE FOR THE INTERIM RESULTS

This announcement is made by Human Health Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**"), pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the **"Board"**) of directors (the **"Directors"**) of the Company wishes to inform the shareholders of the Company (the **"Shareholders"**) and potential investors that based on the information currently available to the Board and the preliminary review of the Group's unaudited consolidated management accounts for the six months ended 31 December 2016 and as compared with the unaudited consolidated management accounts for the six months ended 31 December 2015, the profit attributable to Shareholders for the six months ended 31 December 2016 is expected to decrease by approximately HK$3 million, representing an approximately 31% decrease as compared with that for the corresponding period in 2015.

Based on the relevant information currently available to the Board, the decrease in the profit attributable to Shareholders for the six months ended 31 December 2016 was primarily due to (i) the decrease in revenue for the six months ended 31 December 2016 by approximately HK$4 million which was mainly due to the delayed seasonal flu effect which normally starts from the last quarter in a calendar year. As mentioned in the prospectus of the Company dated 17 March 2016 (the "**Prospectus**"), the Group's business is subject to seasonality. Please refer to the section headed "Risk Factors – Our business is subject to seasonality" in the Prospectus; (ii) the increase in payroll costs to support the Group's business development in Hong Kong and the People's Republic of China (the "**PRC**") and (iii) the increase in other operating costs for the Group's business expansion in Hong Kong and the PRC.

The information contained in this announcement is based on a preliminary assessment by the Board after considering the information currently available and is not based on any financial data or information that has been audited or reviewed by the auditors or the audit committee of the Company. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended 31 December 2016, which is expected to be released by the end of February 2017 and may differ from the information disclosed in this announcement.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By Order of the Board
Human Health Holdings Limited
Chan Kin Ping
Chairman

Hong Kong, 27 January 2017

As at the date of this announcement, the Board comprises Mr. Chan Kin Ping (also as Chief Executive Officer), Dr. Pang Lai Sheung, Ms. Sat Chui Wan and Mr. Poon Chun Pong as executive Directors and Dr. Lui Sun Wing, Mr. Chan Yue Kwong Michael and Mr. Sin Kar Tim as independent non-executive Directors.